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Abstract
A constant relative biological effectiveness (RBE) of 1.1 is currently used in clinical proton therapy.
However, the RBE varies with factors such as dose level, linear energy transfer (LET) and tissue
type. Multiple RBEmodels have been developed to account for this biological variation. To enable
recalculation of patients treated with double scattering (DS) proton therapy, including LET and
variable RBE, we implemented and commissioned a Monte Carlo (MC) model of a DS treatment
nozzle. The main components from the IBA nozzle were implemented in the FLUKAMC code. We
calibrated and verified the following entities to experimental measurements: range of pristine Bragg
peaks (PBPs) and spread-out Bragg peaks (SOBPs), energy spread, lateral profiles, compensator
range degradation, and absolute dose. We recalculated two patients with different field setups,
comparing FLUKA vs. treatment planning system (TPS) dose, also obtaining LET and variable RBE
doses. We achieved good agreement between FLUKA and measurements. The range differences
between FLUKA and measurements were for the PBPs within±0.9 mm (83%⩽ 0.5 mm), and for
SOBPs±1.6 mm (82%⩽ 0.5 mm). The differences in modulation widths were below 5 mm
(79%⩽ 2 mm). The differences in the distal dose fall off (D80%–D20%) were below 0.5 mm for all
PBPs and the lateral penumbras diverged from measurements by less than 1 mm. The mean dose
difference (RBE = 1.1) in the target between the TPS and FLUKA were below 0.4% in a three-field
plan and below 1.4% in a four-field plan. A dose increase of 9.9% and 7.2% occurred when using
variable RBE for the two patients, respectively. We presented a method to recalculate DS proton
plans in the FLUKAMC code. The implementation was used to obtain LET and variable RBE dose
and can be used for investigating variable RBE for previously treated patients.
1. Introduction
The majority of long-term follow-up data from proton therapy are from patients treated with double
scattering (DS) proton therapy. This delivery technique employs scattering and range shifting components to
spread and confirm the beam. One of the benefits of proton therapy vs. conventional radiotherapy with
photons is the reduction of dose to healthy tissue (Lomax et al 1999, MacDonald et al 2008). To relate clinical
photon data to protons, current clinical practice considers protons to be uniformly 10% more effective than
photons, characterized by a relative biological effectiveness (RBE) of 1.1. However, in vitro experiments have
shown that the RBE of protons vary with the linear energy transfer (LET), dose level, tissue fractionation
sensitivity (α/β ratio) and clinical endpoint (Paganetti 2014). A particular increase in RBE towards the end
of the proton beam range due to elevated LET has also been suggested by in vivo experiments (Saager et al
2018). This increase could be problematic for patients with organs at risk (OARs) located near the distal end
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of treatment fields. Moreover, recent studies have indicated a possible correlation between the increased LET
and asymptomatic magnetic resonance (MR) image changes (Bahn et al 2020, Eulitz et al 2019b, Peeler et al
2016, Underwood et al 2018). Still, further investigations are required to understand how and if elevation in
LET/RBE influence the toxicity in OARs.
Multiple models have been developed to account for the variable RBE, both phenomenological models
(Rørvik et al 2018), and biophysical models such as the local effect model (LEM) (Scholz et al 1997, Elsässer
et al 2010) and the microdosimetric-kinetic model (MKM) (Hawkins 1998). To enable correlation studies
between the RBE variation and follow-up data, the LET distributions must be obtainable in combination
with the physical dose for previously treated patients. Calculation of variable RBE dose in commercial
treatment planning systems (TPSs) involved in clinical practice is under development. This advancement will
increase the need of Monte Carlo (MC) codes for comparison and verification purposes. Furthermore, MC
codes have been shown to be more accurate, especially in heterogeneous regions (Paganetti 2012, Schuemann
et al 2015). To recalculate DS proton therapy plans in an MC code, the geometry within the particular
treatment nozzle must be implemented and undergo verification and commissioning, ideally to
experimental measurements acquired at the specific beam delivery unit. DS proton therapy nozzles have
previously been implemented in MC codes such as TOPAS (Perl et al 2012, Testa et al 2013, Shin et al 2017,
Liu et al 2019), Geant4 (Paganetti et al 2004, 2008) and MCNPX (Sayah et al 2013). The FLUKAMC code
(Battistoni et al 2016, Ferrari et al 2005, Böhlen et al 2014) have earlier been applied in recalculation of pencil
beam scanning proton therapy plans (Parodi et al 2012, Mairani et al 2013, Giovannini et al 2016, Fjæra et al
2017, 2020) and carbon ion treatment plans (Böhlen et al 2013, Bauer et al 2014), where the necessary nozzle
geometry to implement is substantially reduced compared with DS nozzles.
The purpose of this study was to develop a system that enables MC recalculation of patients treated with
DS proton therapy, specifically aiming towards LET and variable RBE calculation with phenomenological
models. The DS nozzle geometry was implemented into the MC code and was commissioned and verified to
experimental measurements.
2. Materials andmethods
2.1. The double scattering nozzle
DS proton therapy starts with an initial pencil beam that traverses various nozzle components in order to
spread and confirm the beam both in the lateral and longitudinal directions to cover the entire target volume
with dose. At the University of Florida Health Proton Therapy Institute (UFHPTI), a total of three DS nozzles
from IBA (Ion Beam Applications, Belgium) are installed. The main components of each nozzle are (in
sequence from upstream towards the patient isocenter): first ionization chamber, first scatterers (FS), range
modulator (RM) wheels, second scatterers, variable collimators, second ionization chamber, field mirror,
snouts and lastly patient specific apertures and range compensators. The initial beam is accelerated by a
cyclotron and is steered into the nozzle by powerful magnets. The beam energy directly prior to entering the
nozzle is known, but the beam size, shape, divergence, and energy spread at the nozzle entrance is typically
derived from models. Typical values for the initial beam at the UFHPTI are an angular divergence of 3 mrad
and a Gaussian beam spot size in x and y of 1.41 cm at FWHM. The parameter which affects the beam the
most is the energy spread, which we determined during the nozzle commissioning in the MC software.
2.2. Geometry implementation
The geometry of the most central components of the IBA nozzle at the UFHPTI was implemented into the
FLUKAMC code based on vendor blueprints. FLUKA has a powerful graphical user interface called Flair
(Vlachoudis 2009) which simplifies geometry definition and provides the ability to visualize the geometry
during creation. Most of the components mentioned above were relatively straightforward to implement,
using basic structures such as rectangular parallelepipeds (RPPs), cylinders, cones, and planes. However,
more complex components required advanced solutions for implementation. The geometrical
implementation of these components is described in detail below.
2.2.1. Range modulator wheels
The IBA nozzle contains three different RM wheels, where each wheel has three separate tracks (figure 1)
defined to specify spread-out Bragg peaks (SOBPs) of various ranges and modulation widths. An IBA RM
wheel track has steps with varying thickness, where each step defines a single pristine Bragg peak (PBP). The
number of steps on a wheel track range between 14 and 31, depending on the track. When the wheel rotates
during beam irradiation, the beam sequentially penetrates the different steps which ultimately results in an
SOBP. Each step is made of either Lexan (polycarbonate) or carbon, and these low-Z materials are combined
with steps of lead (high atomic number) in order to provide a constant energy loss while maintaining the
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Figure 1. Illustration of the upstream part of a range modulator wheel consisting of three tracks. The golden sectors are the brass
stop blocks, while each blue sector is a step made of Lexan where darker blue illustrates an increase in step thickness. The beam is
not necessarily turned on (i.e. the start angle) at the zero angle (red dashed line). The correct start angle must be identified (green
dashed line), in order to have the beam stop at the correct position on the wheel (stop angle at green dashed line). Note also that
the beam has a certain size and may therefore stop while overlapping multiple consecutive steps.
scattering power. Every step has different water equivalent thicknesses and angular widths, defining the PBP
pull-back and weight, respectively. A brass stop block is also used at the boundary between the thickest and
thinnest step to ensure that the beam does not penetrate these adjacent steps simultaneously.
During treatment, the beam will be turned on at the start position (i.e. start angle) of the wheel and
begin rotating. The requested modulation width of the SOBP decides the so-called stop angle, which is the
position on the wheel where the beam is turned off. The wheel subsequently rotates back to the start
position, followed by the beam being turned on again, where a complete rotation lasts 100 ms. While this
results in an SOBP, it is not necessarily flat. Thus, in order to maintain a flat SOBP for different initial beam
energies and a limited number of RM wheels, beam current modulation (BCM) is applied at the cyclotron to
regulate the beam intensity (Lu and Kooy 2006). There are 24 BCM files associated with each treatment
nozzle. The BCM file contains 255 weights that specify the beam intensity, used to fine-tune the flatness of
the SOBPs. Each BCM weight is applied at a specific angular position on the wheel track, covering an angle
span of 360◦/255= 1.41◦.
In FLUKA, we implemented each RM track as a cylinder, where the steps were separated using infinite
planes. In order to create an SOBP, the wheel has to rotate in real-time, or the rotation must be modelled by
using probability as described below. To model a rotating wheel and to apply the BCM we implemented the
following algorithm in the FLUKA source user routine: For each primary particle (PP), a weighted random
sampling method is used, where the probability to sample a specific BCM weight is decided by its respective
weight. The angle span of the sampled BCM weight is read out, and subsequently, if the angle span is either
fully or partly within the start and stop angles of the wheel, a random angle within the BCM angle span is
sampled. If this sampled angle is still within the start and stop angles, the wheel is rotated by number of
degrees equal to the sampled angle and the PP is simulated. If the angle span, or sampled angle, is not within
the start and stop angles, an entirely new BCM weight is sampled, and the process is repeated. After a
sufficient number of angles are sampled, and subsequently number of PPs simulated, this method will
perform as a real-time rotating wheel. This solution also considers that the beam spot can be positioned
between multiple consecutive steps.
2.2.2. Apertures
The treatment field specific aperture is used to conform the dose in the lateral direction. The shape of the
aperture opening (defined by coordinates located in the DICOM RT Plan file) is dependent on the target
volume and is typically shaped as an arbitrary polygon. FLUKA does not natively support defining polygons
in the geometry; therefore, we had to approximate the opening by other means.
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Figure 2. (a) Aperture opening defined by a combination of RPPs (magenta) and cylinder. The black crosses indicate the
coordinates of the aperture opening located in the DICOM RT plan. (b) Range compensator in the transverse plane and (c) the
longitudinal plane. The magenta structures indicate the drilling cylinders.
To define the aperture opening in FLUKA, we used RPPs with a base area of 1× 1 mm2. Since a smaller
base area would lead to an increase in CPU time per patient, the base area was chosen as a compromise
between maintaining particle tracking efficiency and keeping a low uncertainty in the definition of the
aperture opening. To increase the efficiency further, the RPPs were restricted to the boundary. The center of
the opening was defined using a cylinder with a radius slightly smaller than the closest distance between
center and aperture opening boundary. Thus, we could approximate the opening using roughly between 500
and 3300 RPPs, highly dependent on the shape and size (figure 2(a)).
The coordinates of the aperture opening, (x,y)iso, are defined in the isocenter plane. As the aperture itself
is located upstream of the isocenter, the coordinates must be projected onto the correct plane. Using the
virtual source axis distance (VSAD) and the isocenter to block tray distance (IBTD) (both located in the






The range compensator confirms the dose to the distal end of the target. It is typically milled from a block
made of Lucite (polymethyl methacrylate). The DICOM RT plan file contains information on the drill bit
diameter, the position of each hole as well as the depth of the drill hole.
To create the range compensator in FLUKA, we defined the outer part as a cylinder made of Lucite. The
drill holes were created by defining partially overlapping cylinders with the same diameter as the drill bit,
while the heights of the cylinders were defined equal to the drill depths in the DICOM file (figures 2(b) and
(c)).
As with the aperture, the drill positions are defined in the isocenter plane following the DICOM
standard. Therefore, the same coordinate transformation as for the aperture had to be conducted, however,
exchanging the IBTD by the isocenter to compensator distance also obtained from the DICOM file.
2.3. Nozzle commissioning
The IBA universal nozzle is capable of creating treatment fields with ranges between 4.6 and 28.4 cm in water
by using beam energies between 155 and 230 MeV. The range interval is divided into eight smaller spans
denoted as options, where each option is labeled B1 to B8. Each option consists of a specific combination of
second scatterer and RM wheel track working in conjunction with the FS to create a flat beam profile with a
specified range and modulation width. Each option is further divided into suboptions where the only
parameters changing within the suboptions are the initial beam energy (i.e. range), modulation width and FS
setting. Furthermore, each suboption is applied a specific BCM. Verification and calibration should therefore
be done for representative beams for each suboption.
All simulations were conducted in FLUKA version 2011.2x using the HADROTHErapy default settings,
with particle transport and delta ray production thresholds set to 100 keV (neutrons: 10−5 eV). Considering
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that all measurements had been conducted in water phantoms and that the TPS calculates the dose to water,
the FLUKA doses were either directly obtained in water or converted to dose to water for other materials.
The depth dose curves for the PBPs and the SOBPs were measured using an IBA PPC05 parallel plate
ionization chamber with a collecting diameter of 1 cm placed in an IBA Blue Phantom water phantom. The
gantry angle was set to 0◦, to avoid irradiation through the phantom wall. The PBPs were created with the
RM wheel in a fixed position, irradiating through the thinnest step. The lateral dose profiles were measured
in an IBA Blue Phantom using an IBA EFD3G electron diode with an active area diameter of 2 mm and a
thickness of 0.06 mm. Relevant details regarding the measurement setup such as air gaps and aperture
openings are specified for each calibrated entity. Such details from the measurement setup were set equal in
the simulation setup. The following sections describe the parameters we calibrated and/or verified to
experimental measurements.
2.3.1. Range calibration
The initial parameter we calibrated was the range of the PBPs. During the range calibration, the energy
spread had not yet been determined. Therefore, we used a fixed energy spread of 0.9 MeV as an approximate
value. As a result, we chose to calibrate the range for the PBPs at the 80% distal dose (DD) level, since the
range at the 80% DD is independent of the energy spread (Gottschalk 2011).
For every option, we selected three PBPs with ranges covered by each suboption. We adjusted the nozzle
settings in FLUKA to correspond to the same setup used for the respective experimental measurements in
water phantoms. The simulated ranges of the PBPs are prone to uncertainties depending on the applied
normalization. To minimize these uncertainties, we normalized the PBPs, for both FLUKA and
measurements, using a theoretical representation of the PBPs called the Bortfeld fit (Bortfeld 1997).
After the simulations, the range difference between FLUKA and measurements at the 80% DD were
obtained. In order to adjust the FLUKA ranges in accordance with measurements, we tuned the initial beam
energy. To find the new FLUKA energy, we rearranged the Bortfeld energy-range relation (Bortfeld and









where EN and EO are the beam energies applied in FLUKA post- and pre-adjustment, respectively.∆R is the
range difference between FLUKA and measurements at the 80% DD while α = 0.0022 cm MeV−1 and
p= 1.77 are coefficients. Furthermore, we verified the calibration by simulating all the PBPs with the new
energies and ensured that we achieved a range agreement to measurements within 0.5 mm.
To apply a systematic calibration for patient recalculations (with vastly different combinations of nozzle
setups), we decided to use a fixed range calibration that was option dependent. Within an option, the nozzle
geometry is permanent except for the different FS settings. Since the FS setting can change within a
suboption, using a suboption-dependent range calibration does not induce increased accuracy. Thus, to
calibrate the ranges in FLUKA, we calculated the mean energy adjustment for each option, hereafter referred
to as themean option energy adjustment, EA, using the following equation:
EA =
∑3
s=1 (EN,s − EO,s)
3
, (3)
where EO,s is the original energy for the PBP in suboption, s, EN,s is the new energy obtained from equation
(2) for the same PBP, and 3 describes the total number of suboptions within an option, i.e. the number of
simulated PBPs per option. We further verified the accuracy of the range calibration and aimed for an
agreement between FLUKA and measurements within 1 mm.
For all the PBPs, the air gap was set to 10 cm and we used an aperture opening of 15× 15 cm2 without a
range compensator. We simulated 15 million PPs and the scoring region was defined as a cylinder with a
diameter of 2 cm and a resolution of 0.5 mm in the longitudinal direction.
2.3.2. Energy spread calibration
The energy spread is dependent on the initial beam energy and determines the slope of the distal dose fall-off
(DDF) for SOBPs and PBPs. The widths of the PBPs are also regulated by the energy spread. To calibrate the
energy spread, we recalculated a total of 14 PBPs spanning energies between 155 and 226 MeV in intervals
between 5 and 15 MeV.
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To compare the FLUKA PBPs to measurements, we evaluated the millimeter differences at multiple dose
levels and regions:
• DD at the 90% to 50% dose levels in 10% intervals,
• DD at the 20% dose level,
• proximal dose (PD) at the 90% to 50% dose level in 10% intervals,
• total width difference (distal-proximal) at the 90% to 50% dose level in 10% intervals,
• DDF, i.e. the difference between the DD at the 80% and 20% dose levels.
The goal was to keep all differences between FLUKA and measurements below 0.5 mm, with the highest
priority at the DD and DDF. The simulations and resulting comparisons were done on a trial-and-error
basis. We started with an energy spread of 0.9 Mev. The simulated PBPs were compared with the
measurements and re-simulated with either a higher or lower energy spread until the PBP met the goals. The
identified energy spreads for the 14 PBPs were plotted against the initial beam energy in order to create an
energy spread calibration curve to be used for subsequent simulations. The simulation setup was identical to
the range calibration setup.
2.3.3. SOBP verification and start angle calibration
A specific combination of range and modulation width for an SOBP determines which option, thus which
RM wheel track and second scatterer to be used. Each RM wheel track has a specific start angle (a position on
the track where the beam is turned on) which is located somewhere on the brass stop block and typically
differs from the zero angle of the wheel track (figure 1). This angle is not provided by the vendor and must be
correctly identified. The stop angle, i.e. where the beam is turned off, determines the modulation width
(defined here as the distance between the distal and proximal 90% dose). Furthermore, the stop angle is
relative to the start angle and not the zero angle for the wheel track. Thus, an incorrect start angle may result
in a modulation width that is either too long or too short. It could also result in a shift of the BCM weights,
leading to incorrect weighting of the PBPs and subsequently either non-flat SOBPs and/or shifts in the
measured oscillations in the plateau region.
To identify the start angles of the wheel tracks, we compared the modulation widths from simulations to
corresponding measurements. We initially started with a start angle defined at the RM wheel zero angle and
adjusted the start angle until the modulation width as well as the BCM corresponded to measurements. We
simultaneously evaluated the range differences of the SOBPs. We aimed for range differences between
FLUKA and measurements 1 mm and modulation width differences below 2 mm.
The start angles were obtained on trial-and-error basis; thus, 20 million PPs histories were initially
simulated to reduce computational time. The energies and energy spreads used were obtained from the
calibration, i.e. using the mean option energy adjustment as well as the energy spread curve. When the RM
wheel start angle provided SOBPs that corresponded to the measurements, we verified the start angle by
increasing the number of PPs to 100 million to ensure sufficient statistical accuracy. We used the same
scoring definition as for the range calibration and the aperture opening was set to 15× 15 cm2 and the air
gap to 10 cm. The SOBPs were normalized to the mean dose between the center of the SOBP plateau and
±25% of the modulation width.
2.3.4. Aperture and range compensator verification
We also verified the lateral dose profiles collimated by brass apertures. We simulated an SOBP with a range of
15.1 cm and a modulation width of 10.4 cm. The field was collimated using three different apertures with
openings of 3× 3 cm2, 6× 6 cm2, and 10× 10 cm2. We evaluated the differences between the measurements
and the simulations at the 90% to 10% dose level in 10% intervals, in addition to the 80%–20% lateral
penumbras.
Measurements of the lateral dose profiles had been taken at three different depths; 0.5 cm, 9.9 cm, and
14.1 cm. We scored the dose from the profiles in FLUKA at the same depths, with a longitudinal bin size of
1 mm. The bin size in the lateral direction was 0.5 mm and we simulated 200 million PPs. The air gap was set
to 10 cm and the source surface distance (SSD) to 220 cm, identical to the measurement setup. The doses
from the simulated and measured profiles were normalized to the mean dose between±0.5 cm from the
central axis.
In order to verify the range compensator implementation in FLUKA, we simulated an SOBP penetrating
a stair-shaped range compensator and compared with measurements as well as the Eclipse TPS (Varian
Medical Systems, Palo Alto, CA, USA). The range compensator consisted of Lucite with a density of
1.2 g cm−3 and three different thicknesses of 5.3 cm, 2.7 cm, and 0.1 cm. The SOBP had a range of 15.1 cm
and a modulation width of 9.1 cm. We compared the dose in both the lateral and longitudinal directions at
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different depths and offsets from the central axis. The doses from the simulations, measurements and the
TPS were normalized using the same methods as described for the apertures and SOBPs. Furthermore, we
compared the 2D dose distributions from FLUKA and the TPS using the stair-shaped range compensator.
The dose from the FLUKA simulation was normalized according to the absolute dose calibration described in
the next section. The radius of the circular aperture opening was 6 cm. We simulated 300 million PPs and
scored the dose in a 360× 360× 165 grid with voxel sizes of 0.5× 0.5× 1 mm3, the latter being in the
longitudinal direction.
2.3.5. Absolute dose calibration
The output factor describes the relationship between the delivered dose and the treatment machine output.
In proton therapy, the machine output is specified in monitor units (MU), where a MU corresponds to a
certain amount of collected charge in the ionization chamber within the nozzle. At the UFHPTI, an
analytical model is used to predict the output factor for patient treatment fields in order to reduce the
number of calibration measurements (Kooy et al 2003, 2005).
Monte Carlo simulations typically express the dose calculation in the form of relative dose, i.e. the dose
per PP. However, it is usually beneficial to have the MC tool represent the dose in absolute units; thus, we
implemented a method to obtain the relationship between the number of PPs and the delivered dose.
The ratio between the number of PPs and the delivered dose (PP ratio) is dependent on the nozzle setup,
i.e. the treatment option, similar to the output factor (Kooy et al 2003). The PP ratio within a treatment
option is also dependent on both the range and modulation width. By dividing the entire range span
available for the treatment nozzle (4.6–28.4 cm) into small intervals, we can have the PP ratio as functions of
only modulation width. Therefore, we obtained the relationship between the modulation width and the PP
ratio for each suboption.
For every suboption we selected six SOBPs with varying modulation widths. Prior to the simulations, the
water phantom in FLUKA was moved such that the center of the plateau of the SOBP was placed in the
isocenter. The SOBP was simulated in FLUKA and we obtained the relative dose at the isocenter (expressed as
Gy/PP). By taking the inverse of the relative dose, we obtained the PP ratio (PP/Gy) for the specific SOBP.
This process was repeated for each of the six SOBPs within the suboption. We fitted curves describing the
relationships between the modulation widths and PP/Gy for each suboption. By inputting the delivered dose
from the treatment field information, we could thus calculate the number of PPs to normalize the FLUKA
output in order to have the dose in absolute units. All SOBPs were simulated using 200 million PPs.
2.4. Patient recalculations
A final goal of the nozzle implementation is to obtain LET and variable RBE dose from proton therapy plans
to further enable correlation studies of follow-up data from patients treated with DS proton therapy.
Therefore, we wanted to compare the nozzle implementation and commissioning to the already
commissioned Eclipse TPS at the UFHPTI.
We selected two anonymous pediatric posterior fossa tumor patients for recalculation. Both patients
received total doses of 54 Gy(RBE) to the PTV using three fields for patient 1 and four fields for patient 2. In
addition, patient 2 had experienced symptomatic brainstem injury. The patient CT images were converted to
FLUKA voxel files by using a built-in function in Flair. The Hounsfield units (HUs) from the CT images were
converted to material composition by the conventions of (Schneider et al 2000) and (Parodi et al 2007).
TPSs typically use the material density as well as the relative stopping power to characterize the radiation
energy loss in different tissues for photons and protons, respectively. The material densities and stopping
powers are related to the HUs acquired by the CT scanner. Thus, in order to have an unbiased comparison
between two different dose calculation systems, the same calibration curves must be used. Therefore, the HU
to material density curve was directly imported into FLUKA. To implement the HU to relative stopping
power curve, we simulated PBPs in a total of 85 phantoms with different HUs ranging between−974 and
3071. The range at the 80% DD were read out and compared with the estimated ranges from the stopping
power calibration curve. Similar to the range calibration, we used Bortfeld fits for normalization of the PBPs.
We applied density correction factors to the HUs in the FLUKA voxel file such that the ranges would
correspond to the stopping power curve and re-simulated the PBPs in order to verify the range adjustments.
We scored doses in a 2 cm diameter cylinder using a 0.5 mm longitudinal resolution and simulated each PBP
using 15 million PPs.
By convention, commercial TPSs calculate the dose to water (Dw) as opposed to MC codes which by
default calculates the dose to material. Thus, in order to directly compare the two systems, the Dw must also
be calculated for the MC code. The Dw in each voxel was obtained using:
Dw = ϕ · LETd, (4)
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where Φ is the fluence for all particles in each voxel and LETd is the dose-averaged LET in water. The LETd
calculation was implemented in our MC workflow in a previous study (Fjæra et al 2017). The LETd in water













where Φi(E) is the fluence of particle type, i, with kinetic energy, E, LETi(E) is the unrestricted LET for the
same kinetic particle, i, and ρw is the density of water (1 g cm−3).
We scored the RBE = 1.1 dose and LETd on the same grid as for the TPS and simulated the patients using
a total of 300 million PPs per treatment field yielding a mean statistical uncertainty below 1% in the target
region. The LETd was scored for primary and secondary protons. We also evaluated the agreement between
FLUKA and the TPS using gamma tests.
Furthermore, our group has previously implemented and analyzed all published phenomenological RBE


































where Dp is the physical dose from protons per treatment fraction, αx and βx are parameters in the
linear-quadratic model for the reference photon radiation, and RBEmax and RBEmin describe the RBE at the
lower and upper dose limits, respectively.
By employing equation (6), we calculated the variable RBE-weighted dose in each voxel using the
McNamara model (MCN) (McNamara et al 2015) including the RBE distribution. The RBEmax and RBEmin

































For the variable RBE calculations, an (α/β)x ratio of 2.1 was used (Meeks et al 2000).
3. Results
Figure 3 shows the completed IBA universal nozzle implemented in FLUKA. Using in-house developed
scripts, the nozzle setup, as well as the patient position and scoring grid, can be automatically defined for
each patient.
3.1. Range calibration
The mean option energy adjustments ranged between−0.92 MeV and 0.73 MeV (appendix table A1). Prior
to tuning the initial beam energies in FLUKA, the difference in PBP ranges between FLUKA and
measurements could reach up to 2 mm (figure 4). By adjusting the FLUKA beam energies using the mean
option energy adjustment in equation (3), we achieved range differences for all options within±0.9 mm,
where the largest range differences occurred for the high range beams. For reference, the figure also shows
the range difference when adjusting the energy specific to each PBP obtained from equation (2).
3.2. Energy spread calibration
The simulated PBPs were in good agreement with measurements after using the correctly identified energy
spreads (figure 5(a)). The relationship between the initial beam energy and energy spread was obtained from
the 14 simulated PBPs (figure 5(b) and appendix table A2). Comparing to measurements, we achieved
differences in DDF below 0.5 mm, and the differences between the 90% DD, 20% DD, and 90% PD were
below 0.2 mm, 0.2 mm, and 0.5 mm for all PBPs, respectively (appendix table A3).
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Figure 3. The nozzle implemented in FLUKA. Component distances have been reduced for better visibility. Some components are
interchangeable for each treatment field; thus, all component varieties are not shown such as other modulator wheels, second
scatterers or snouts. Modified from the Flair geoviewer.
Figure 4. The range differences between PBPs from FLUKA and measurements (FLUKA-measurement) after the mean option
energy adjustment (green dots). The range differences before energy adjustments (blue triangles) and after PBP specific energy
adjustment (red squares) are also shown for reference. The vertical lines divide the range spans covered by each nozzle option.
Figure 5. (a) A pristine Bragg peak after the energy spread calibration. The solid and dashed lines represent the Bortfeld fits in the
peak region, while the green dotted line shows the dose difference between the two Bortfeld fits (FLUKA-measurement) specified
on the right y-axis. (b) Estimated energy spreads and calibration curve.
9
Phys. Med. Biol. 65 (2020) 225033 L F Fjæra et al
Figure 6. (a) Five measured and simulated SOBPs of various ranges and modulation widths. The requested ranges (R) and
modulation widths (M) are specified above the plateau regions for each SOBP. (b) Range differences (FLUKA-measurement) and
(c) modulation width differences (FLUKA-measurement) for 28 calibrated SOBPs. The SOBPs in (a) have been normalized to
different dose levels for illustration purposes.

















Figure 7. Lateral dose profiles at penetration depths of (a) z= 0.5 cm, (b) z= 9.9 cm, and (c) z= 14.1 cm in a water phantom for
an SOBP with a range of 15.1 cm and modulation width of 10.4 cm. The dose profiles have been created using a 3× 3 cm2,
6× 6 cm2 and 10× 10 cm2 aperture opening. The profiles have been normalized to different dose levels for illustration purposes.
3.3. SOBP verification and start angle calibration
After the RM wheel start angles had been identified, the SOBPs showed good agreement between the
measurements and FLUKA, particularly in the SOBP plateau regions and the distal parts (figure 6(a) and
appendix table A4). The oscillations in the SOBP plateaus were also correctly modelled in FLUKA,
confirming a good agreement between the RM wheel start angle and the BCM. Overall, the ranges for most
of the SOBPs we verified were within±1 mm of the measurements, with only 2 out of 28 SOBPs having
range differences up to 1.6 mm (figure 6(b)). The differences in modulation widths were below 2 mm in
most cases. However, some SOBPs had larger differences up to 5 mm (figure 6(c)).
3.4. Aperture and range compensator verification
The lateral dose profiles from the aperture simulations showed good agreement with the measurements
(figure 7). For all evaluated aperture openings and depths, we achieved differences between FLUKA and
measurements for the 80%–20% lateral penumbras below 1 mm (appendix table A5). FLUKA did, however,
typically show slightly sharper penumbras compared with the measurements.
Using the stair-shaped range compensator, the lateral dose profiles from FLUKA matched the
measurements very well (figure 8). The dose oscillations resulting from multiple Coulomb scattering at the
range shifter boundaries were also reproduced by FLUKA at depths of 3.7 cm, 6.7 cm and 9.7 cm (figures
8(a)–(c)), while the TPS predicted the dose less accurately in these areas. The pullback in the longitudinal
dose profiles and the flatness of the SOBPs were in good agreement with measurements with range
differences at the 90% DD below 1 mm (figures 8(e) and (f)).
The differences in the dose were minor when comparing 2D dose distributions between FLUKA and the
TPS. However, there were some inconsistencies at the location of the dose oscillations/range shifter
boundaries (figure 9), also visible in the lateral profiles (figure 8).
3.5. Absolute dose and patient recalculation
By simulating six SOBPs for each suboption within a nozzle option, we were able to predict the relationship
between the number of primary particles and dose as functions of the modulation width (figure 10 and
appendix table A6).
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Figure 8. Lateral profiles from measurements (red solid line), FLUKA (blue dashed line), and Eclipse TPS (green dotted line) at
penetration depths of (a) z = 3.7 cm, (b) z = 6.7 cm, (c) z = 9.7 cm, and (d) z = 12.7 cm in a water phantom for an SOBP with a
range of 15.1 cm and modulation width of 9.1 cm when using a stair-shaped range compensator. Depth dose curves at distances
from the central axis of (e) x=−4.0 cm and (f) x= 4.0 cm. The positions are indicated by the white dashed lines in figure 9(a).
The FLUKA recalculated RBE = 1.1 dose distribution for patient 1 was in very good agreement with the
original TPS dose (figure 11). There were no substantial range differences and minor lateral dose differences.
The mean dose to the PTV was 54.7 Gy(RBE) in the TPS and 54.9 Gy(RBE) in FLUKA. The brainstem mean
dose was also 0.2 Gy(RBE) higher in FLUKA, compared with a TPS dose of 49.5 Gy(RBE) (figure 12(a) and
appendix table A7). The difference in the maximum dose (D0.1cc) between the two dose calculation systems
was 0.3 Gy(RBE) for both the PTV and the brainstem. We obtained 3%/3 mm gamma pass rates of 100% in
the PTV and 98.8% in the entire brain. The variable RBE-weighted mean dose from the MCN model was, as
expected, higher compared with the RBE = 1.1 doses from FLUKA and the TPS dose, increasing to
60.1 Gy(RBE) in the PTV and 54.2 Gy(RBE) in the brainstem. The LETd increased at the distal part of the
treatment fields leading to a high LETd edge (figure 11(e)), and a mean LETd in the brainstem of
2.3 keV µm−1. This further resulted in visible increase in RBE from the MCN model in the same area with a
mean RBE in the brainstem of 1.2 (figure 12(b)).
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Figure 9. 2D dose distributions from (a) FLUKA and (b) Eclipse TPS, in addition to (c) dose difference between FLUKA and the
Eclipse TPS when using a stair-shaped range compensator. The Eclipse TPS dose is subtracted from the FLUKA dose in the
difference plot. The white dashed lines indicate the locations of the dose profiles in figure 8. The FLUKA dose was normalized
according to the absolute dose calibration.
Figure 10. Primary particles per unit dose as functions of the modulation width for each suboption within nozzle options: (a) B3,
(b) B4, (c) B5, and (d) B6. A separate curve was fitted for smaller range spans, i.e. suboptions (e.g. B3_1: 7.49–8.12 cm, B3_2:
8.12–8.81 cm, B3_3: 8.81–9.55 cm).
For patient 2, there was a difference of 1.4% in the mean dose to the PTV. Using FLUKA we found a mean
dose to the PTV of 54.7 Gy(RBE) and 35.5 Gy(RBE) to the brainstem while the TPS dose was 55.5 Gy(RBE)
to the PTV and 35.4 Gy(RBE) to the brainstem (figure 12(a) and appendix table A7). The D0.1cc was lower by
2.4% and 2.0% in FLUKA compared with the TPS in the PTV and brainstem, respectively. The gamma tests
yielded 3%/3 mm pass rates of 92.2% in the PTV and 90.8% in the brain. The mean LETd in the brainstem
was 4.4 keV µm−1, resulting in a mean RBE of 1.4 from the MCN model (figure 12(b)).
4. Discussion
In this paper, we presented the first implementation of an IBA DS proton therapy nozzle in the FLUKAMC
code. Ranges and distal dose fall-offs of pristine Bragg peaks and SOBPs were calibrated with millimeter
precision and lateral penumbras were verified with good accuracy. Implementation of patient-specific
components was successfully verified, and we also obtained LET and RBE distributions in addition to
12
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Figure 11. 2D distributions for patient 1 with one vertex and two posterior fields. (a) FLUKA recalculated RBE= 1.1 dose, (b)
TPS RBE= 1.1 dose, (c) McNamara variable RBE dose, (d) RBE= 1.1 dose difference between FLUKA and TPS where the latter
is subtracted from the former, (e) LETd calculated in FLUKA, and (f) is the RBE calculated using the McNamara model. Voxels
with RBE= 1.1 dose below 1 Gy(RBE) has been set transparent for all panels. The PTV is delineated in magenta while the
brainstem is marked in red.
Figure 12. Volume histograms for the PTV and brainstem for patient 1 (P1, solid lines) and patient 2 (P2, dashed lines). (a) Dose
volume histograms from the TPS and FLUKA. (b) LETd volume histograms and RBE volume histograms for the McNamara
model.
variable RBE-weighted doses for patients in FLUKA. Overall, the FLUKA simulations were in good
agreement with the experimental measurements, enabling studies of LET/RBE.
We evaluated the range for a total of 28 different SOBPs, where the range differences between FLUKA and
measurements were below 1 mm for all except two SOBPs. Similar accuracy for DS in other MC
commissioning studies have been reported for Geant4 (Paganetti et al 2004, Kim et al 2012), TOPAS (Testa
et al 2013, Shin et al 2017, Liu et al 2019) and MCNPX (Sayah et al 2013). The modulation width differences
were below 5 mm for all cases, and below 2 mm for 79% of the cases. The largest modulation width
differences occurred mainly for SOBPs with long modulation widths, leading to a relatively flat shoulder in
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the proximal region. This can result in inaccuracies in determining the correct position of the 90% PD for
simulations; due to a higher statistical uncertainty in determining the position (Testa et al 2013), and for
measurements; since a slight difference in dose normalization or measurement setup may lead to large
differences in the 90% PD (Lu and Flanz 2011). This could partly explain the increase we observed for the
modulation width differences. We chose to evaluate the modulation widths using the same definition as
applied at the UFHPTI, i.e. the distance between the 90% DD and 90% PD. However, an alternative
approach is to define the modulation width between the 90% DD and the 98% PD where the gradient is
steeper (Engelsman et al 2009).
By using a mean value for the energy adjustment for each option when calibrating the range for the Bragg
peaks, we achieved overall range differences between FLUKA and measurements below 0.9 mm for the PBPs
and below 1.6 mm for the SOBPs. To calibrate the ranges, we could have also adjusted parameters such as
ionization potentials and material densities. However, these are parameters with potentially high
uncertainties. For example, the densities used for the materials in the geometry implementation were
provided by the vendor, where the exact material densities used in a nozzle may often not be known to a
sufficient accuracy (Paganetti 2012). Even a slight discrepancy may introduce significant range differences
(Bednarz et al 2011). We also maintained the standard values for ionization potentials defined in FLUKA,
originating from the ICRU reports. For example, the ionization potential for water was set to 75 eV; however,
there have been reports of ionization potentials for water between 75 and 81.8 eV, leading to potential range
uncertainties (Kumazaki et al 2007). Therefore, the adjustments were restricted to beam energies only, in
order to avoid extended error propagation.
To obtain the FLUKA dose in absolute units, we obtained the direct relationship between the number of
PPs and the delivered dose (Clasie et al 2011). Another commonly used method is to relate the MC dose to
the MU machine output to obtain the MC specific output factors. This is done by simulating the charge
collected by the ionization chamber in the nozzle. However, the measurement volume in the ionization
chamber is typically small and is filled with air which has low density. This therefore requires a substantial
amount of PPs to be simulated to obtain a chamber response with sufficient statistics (Paganetti 2006). The
output factor dependency in passive scattering proton therapy can be expressed as functions of a single
factor, r= (R-M)/M, where R andM is the range and modulation width, respectively. In our case, we defined
the absolute dose calibration curves as functions of modulation width and defined separate curves for small
range spans, as we observed a more well-defined relationship between the number of PP and delivered dose
in this case. Furthermore, some curves were very similar for different range spans within an option (e.g.
option B4 in figure 10). However, we chose to keep separate curves within each option, as they were very
sensitive to small changes, whereas using combined curves lead to increased dose differences compared with
the TPS dose.
To achieve a mean statistical uncertainty below 1% in the target region, we simulated each patient
treatment field using a total of 300 million PPs. This resulted in an average of 800 CPU-hours for each patient
on our fastest CPU, an Intel Xeon Gold 6248, or 10 h distributed among the 80 available cores. In DS proton
therapy, the majority of the simulation time is used to track the particles within the nozzle. Furthermore, for
an aperture with a small opening of 3 cm in diameter, the efficiency can be as low as 0.7% increasing to
17.7% for a 15 cm diameter aperture opening (Paganetti 2011). For pencil beam scanning proton therapy,
the beam does not interact with considerable amounts of geometry making the efficiency substantially
higher. It is also possible to further reduce the simulation time for pencil beam scanning by creating a phase
space file and reuse it for different patients and treatment fields that use the same treatment setup. The phase
space approach is not practical to use in DS proton therapy as a measure to reduce the simulation time since
the nozzle setup is typically completely different for each treatment field. The efficiency in DS proton therapy
can, however, be improved by techniques such as geometrical particle splitting and Russian roulette (Eulitz
et al 2019a, Ramos-Méndez et al 2013, Ramos Méndez et al 2015). However, phase space simulations do have
another purpose in DS proton therapy. In order to reduce the lateral scattering, the air gap (distance between
the range compensator and the patient) is kept as small as possible. Depending on the MC code, this may
result in an overlap between patient specific components and the patient geometry, potentially leading to
problems related to particle tracking in overlapping regions. This scenario occurred for one of our patients.
We solved this by cropping/removing irrelevant areas surrounding the patient, thus avoiding overlap.
However, when simulating a large number of patients, cropping CT images in the MC code is impractical
and time consuming. Therefore, by separating the tracking of particles within the nozzle into a phase space
file containing particle type, energy, position, and direction, the dose simulation can be started within the
patient geometry, avoiding unambiguity due to overlapping regions (Paganetti et al 2008).
The range of estimated mean LETd values for the two posterior fossa tumor patients was
2.3–4.4 keV µm−1 in the brainstem and 2.4–2.5 keV µm−1 in the target region. Similar ranges have been
reported in a study of central nervous system (CNS) injury for pediatric medulloblastoma patients treated
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with DS proton therapy (Giantsoudi et al 2016). In their study, the authors did not find any statistically
significant differences in LETd values between patients with and without CNS injury. In our case, the patient
receiving a mean LETd of 4.4 keV µm−1 in the brainstem did also experience symptomatic brainstem injury.
This may be a coincidence, but a thorough investigation for similar patients is warranted.
5. Conclusions
We implemented and commissioned a DS proton therapy nozzle into the FLUKAMC code. Methods for the
entire process was described, from solutions on how to implement complex geometries such as rotating
range modulator wheels as well as apertures and compensators, to the procedure of calculating variable RBE
and LET. Overall, we achieved excellent agreement between the MC code and measurements and also
accomplished good agreement between MC and the TPS for two patient cases. Considering that the UFHPTI
has one of the most extensive cohorts of patients treated with proton therapy, the nozzle implementation





This work was partly funded by the Trond Mohn Foundation (funding no. BFS2015TMT03).
Appendix
Table A1.Mean option energy adjustments for each nozzle option.









Table A2. Fit function and model diagnostics for the energy spread calibration curve. E denotes the initial beam energy.
Fit function, dEE (%) 8.98 · 10
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Table A3. Requested, measured and FLUKA ranges as well as the range differences between measurements and FLUKA for pristine Bragg
peaks (FLUKA-measurement). The table also lists a comparison between the measured and FLUKA 80%–20% distal dose fall-off.
Range (mm) Distal dose fall-off (80%–20%) (mm)
Requested Measurement FLUKA Difference Measurement FLUKA Difference
46.0 47.5 47.3 −0.2 3.5 3.6 0.1
80.0 81.8 81.7 −0.1 3.6 4.1 0.4
85.0 86.7 86.7 0.0 3.7 3.9 0.2
100.0 102.3 102.3 0.0 4.0 4.1 0.1
105.0 107.4 107.5 0.0 4.0 4.0 0.0
110.0 112.6 112.6 0.0 4.0 4.0 0.0
125.0 126.4 126.3 −0.1 3.6 4.1 0.5
135.0 135.5 135.5 −0.1 4.0 4.3 0.3
165.0 168.5 168.3 −0.1 4.5 4.5 0.0
175.0 178.7 178.6 −0.1 4.6 4.7 0.1
185.0 188.2 188.2 0.0 4.6 4.7 0.0
210.0 213.6 213.5 −0.1 4.8 5.0 0.1
220.0 222.3 222.3 0.1 5.0 5.0 0.1
275.0 277.8 277.7 −0.1 4.9 5.0 0.1
Table A4. Ranges and modulation widths for a selection of spread-out Bragg peaks. For the differences, the measured values are
subtracted from the FLUKA values.
Range (mm) Modulation width (mm)
Requested Measurement FLUKA Difference Requested Measurement FLUKA Difference
84.1 84.8 84.5 −0.4 50.0 50.5 50.5 0.0
100.2 101.1 101.1 0.1 55.0 54.7 54.2 −0.5
126.0 125.7 125.5 −0.3 30.0 30.2 30.0 −0.2
165.0 167.0 167.3 0.3 50.0 49.8 48.9 −0.9
185.0 186.1 186.8 0.7 70.0 70.1 69.8 −0.3
Table A5. Left side 80%–20% lateral penumbras at penetration depths of z = 0.5 cm, z = 9.9 cm, and z = 14.1 cm in a water phantom
for an SOBP with a range of 15.1 cm and modulation width of 10.4 cm. For the differences, the measured values are subtracted from the
FLUKA values.
Depth (z)= 0.5 cm Lateral penumbras (mm)
Aperture opening (cm2) Measurement FLUKA Difference
3× 3 3.3 2.8 −0.5
6× 6 3.4 2.6 −0.8
10× 10 3.1 2.5 −0.6
Depth (z)= 9.9 cm Lateral penumbras (mm)
Aperture opening (cm2) Measurement FLUKA Difference
3× 3 6.1 5.7 −0.3
6× 6 6.2 5.7 −0.5
10× 10 6.2 5.4 −0.8
Depth (z)= 14.1 cm Lateral penumbras (mm)
Aperture opening (cm2) Measurement FLUKA Difference
3× 3 7.8 7.5 −0.3
6× 6 7.8 7.6 −0.2
10× 10 8.0 7.2 −0.8
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Table A6. Fit functions and model diagnostics for the dose to primary particles calibration curves (PP/Gy) for nozzle options B3–B6.
mw denotes the requested modulation width for an SOBP.
Option B3




3.24 · 1011 · ln(mw)+ 4.57 · 1011 3.23 · 1011 · ln(mw)+ 4.42 · 1011 3.29 · 1011 · ln(mw)+ 4.17 · 1011
R2 0.996 0.998 0.985
p-values
Intercept 1.03 · 10−5 1.38 · 10−6 2.40 · 10−4
ln(mw) 7.20 · 10−6 7.33 · 10−7 8.23 · 10−6
Option B4




3.32 · 1011 · ln(mw)+ 4.52 · 1011 3.32 · 1011 · ln(mw)+ 4.61 · 1011 3.39 · 1011 · ln(mw)+ 4.46 · 1011
R2 0.988 0.986 0.989
p-values
Intercept 1.45 · 10−4 1.91 · 10−4 1.64 · 10−4
ln(mw) 5.30 · 10−5 7.24 · 10−5 4.54 · 10−5
Option B5




2.85 · 1011 · ln(mw)+ 3.40 · 1011 2.58 · 1011 · ln(mw)+ 3.88 · 1011 2.72 · 1011 · ln(mw)+ 3.40 · 1011
R2 0.996 0.994 0.996
p-values
Intercept 2.69 · 10−5 3.27 · 10−5 3.10 · 10−5
ln(mw) 4.18 · 10−6 1.27 · 10−5 3.88 · 10−6
Option B6




2.58 · 1011 · ln(mw)+ 3.67 · 1011 2.62 · 1011 · ln(mw)+ 3.57 · 1011 2.58 · 1011 · ln(mw)+ 3.56 · 1011
R2 0.997 1 0.979
p-values
Intercept 1.40 · 10−5 1.44 · 10−7 1.71 · 10−3
ln(mw) 3.03 · 10−6 2.28 · 10−8 1.65 · 10−4
Table A7.Mean dose and maximum dose (D0.1cc) for patient 1 and 2. The dose metrics was obtained in the PTV and the brainstem for
the dose calculations from the TPS, FLUKA RBE= 1.1 (RBE1.1) and the McNamara (MCN) model.
Patient 1 Patient 2
PTV Brainstem PTV Brainstem
Metrics (Gy(RBE)) TPS RBE1.1 MCN TPS RBE1.1 MCN TPS RBE1.1 MCN TPS RBE1.1 MCN
Mean dose 54.7 54.9 60.1 49.7 49.5 54.2 55.5 54.7 59.5 35.4 35.5 43.0
D0.1cc 55.9 56.2 62.8 55.0 55.3 60.5 57.7 56.3 62.4 56.1 55.0 62.6
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